R1 plans to initiate a Phase IIb study of AP306 later this year.

Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care; Partnership with Alebund Pharmaceuticals to gai ...

Immunome is advancing varegacestat for desmoid tumors, targeting NDA submission in Q2 2026 after positive phase 3 RINGSIDE ...

In this monthly news roundup, we take a look back at top moments from the pharmaceutical industry. It’s time to reflect on ...

The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory milestones accumulate(1) . The Drug ...

By Ludwig Burger and Patricia Weiss FRANKFURT, March 5 (Reuters) - Germany's Merck KGaA projected 2026 adjusted operating profit to slip by as much as 9.8%, hurt by negative currency effects and the ...

Merck KGaA expects its 2026 adjusted operating profit to decrease by up to 4%, excluding currency effects, according to its latest statement.

Investing.com -- Merck KGaA (ETR:MRCG) on Thursday warned adjusted operating profit margins would shrink in 2026 as patent ...

White House messaging appeared to quickly influence medical practice ...

Everyone’s favorite bracket challenge has returned. That’s right—it’s time once again for Fierce Pharma Marketing’s annual ...

Merck KGaA forecast a sluggish year ahead, with the possibility of falling profits, as generic competition for its multiple sclerosis drug Mavenclad weighs on its health care division. The German ...